Previous 10 | Next 10 |
Image source: The Motley Fool. Provention Bio, Inc (NASDAQ: PRVB) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: Provention Bio, Inc (PRVB) Q3 2020 Earnings Call Transcript
Provention Bio (PRVB): Q3 GAAP EPS of -$0.56 misses by $0.14.Cash, cash equivalents and marketable securities of $147.2MPress Release For further details see: Provention Bio EPS misses by $0.14
Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business Update - Completed rolling submission of the Biologics License Application (BLA) for teplizumab in the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals - - Launched ...
Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rolling BLA submission is complete. Financials and insider interest look good. For furthe...
Provention Bio (PRVB) has completed its rolling U.S. marketing application for teplizumab for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk people, a Breakthrough Therapy-tagged indication. The company has requested Priority Review which, if granted, will shorten the re...
Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals - Submission of chemistry, manufacturing and controls (CMC) and administrative information modules...
Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020 PR Newswire RED BANK, N.J., Oct. 29, 2020 RED BANK, N.J. , Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharma...
Gainers: [[DSS]] +26.5%. [[PRVB]] +8.4%. [[GRTS]] +4.7%. [[LILA]] +3.4%. [[NVTA]] +3.1%.Losers: [[ATHM]] -6.9%. [[MRIN]] -5.2%. [[CRMD]] -3.8%. [[QLYS]] -3.3%. [[CBAY]] -2.3%. For further details see: DSS, PRVB, ATHM and QLYS among after-hours movers
Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D) - Healthcare professional and patient campaigns focus on screening for early-stage T1D- PR Newswire RED BANK, N.J., Oct. 1, 2020 RED BANK, N.J. , Oct. 1, 2020 /PRNe...
Provention Bio (PRVB) reports that it has filed the clinical module of its rolling U.S. marketing application for teplizumab (PRV-031) for the delay or prevention of type 1 diabetes (T1D) in at-risk people.It initiated the process in April with the submission of the nonclinical module. It exp...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...